{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:01:45Z","timestamp":1775588505378,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004082","name":"Korean Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clcc.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T22:28:52Z","timestamp":1603837732000},"page":"101-112.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice"],"prefix":"10.1016","volume":"20","author":[{"given":"Yeong Hak","family":"Bang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8491-703X","authenticated-orcid":false,"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sook","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choi Ki","family":"Eun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9522-1997","authenticated-orcid":false,"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.10.001_bib1","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2020.10.001_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2014.59.7633","article-title":"Metastatic colorectal cancer: current state and future directions","volume":"33","author":"Fakih","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12885-016-2734-y","article-title":"Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis","volume":"16","author":"Botrel","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2020.10.001_bib4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/13543784.2016.1161754","article-title":"Novel anti-angiogenic therapeutic strategies in colorectal cancer","volume":"25","author":"Tampellini","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clcc.2020.10.001_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clon.2014.03.001","article-title":"Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin\u00ae Registry\u2013Investigation of Effectiveness and Safety (ARIES) observational cohort study","volume":"26","author":"Hurwitz","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clcc.2020.10.001_bib6","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.10.001_bib7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2011.38.9650","article-title":"Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer","volume":"30","author":"Meyerhardt","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1634\/theoncologist.2017-0314","article-title":"Effectiveness of first-line bevacizumab in metastatic colorectal cancer: the observational cohort study GRETA","volume":"24","author":"Franchi","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.10.001_bib10","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","article-title":"ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making","volume":"23","author":"Schmoll","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib11","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2006.06.8353","article-title":"Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial","volume":"24","author":"Portier","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib12","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1245\/s10434-006-9068-y","article-title":"Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy","volume":"14","author":"Kornprat","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jamcollsurg.2006.12.036","article-title":"Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents","volume":"204","author":"Parks","year":"2007","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.clcc.2020.10.001_bib14","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","article-title":"Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials","volume":"26","author":"Mitry","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.10.001_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000342429","article-title":"Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer","volume":"84","author":"Turan","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.clcc.2020.10.001_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hpb.12138","article-title":"Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey","volume":"16","author":"Rong","year":"2014","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.clcc.2020.10.001_bib17","first-page":"e140","article-title":"A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab in patients with upfront resectable hepatic colorectal metastases","volume":"19","author":"Chun","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.10.001_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pharmthera.2013.09.003","article-title":"Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster","volume":"141","author":"Mountzios","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clcc.2020.10.001_bib19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/bjc.1964.55","article-title":"Dynamics of tumor growth","volume":"13","author":"Laird","year":"1964","journal-title":"Br J Cancer"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820301390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:42Z","timestamp":1761520002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820301390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1533002820301390"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.10.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}